Inhibikase Therapeutics (IKT) Competitors $3.20 +0.04 (+1.27%) (As of 12/20/2024 05:40 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends IKT vs. ADPT, PSTX, IMTX, LENZ, REPL, RLAY, AVXL, AUTL, CGEM, and TECXShould you be buying Inhibikase Therapeutics stock or one of its competitors? The main competitors of Inhibikase Therapeutics include Adaptive Biotechnologies (ADPT), Poseida Therapeutics (PSTX), Immatics (IMTX), LENZ Therapeutics (LENZ), Replimune Group (REPL), Relay Therapeutics (RLAY), Anavex Life Sciences (AVXL), Autolus Therapeutics (AUTL), Cullinan Therapeutics (CGEM), and Tectonic Therapeutic (TECX). These companies are all part of the "biological products, except diagnostic" industry. Inhibikase Therapeutics vs. Adaptive Biotechnologies Poseida Therapeutics Immatics LENZ Therapeutics Replimune Group Relay Therapeutics Anavex Life Sciences Autolus Therapeutics Cullinan Therapeutics Tectonic Therapeutic Adaptive Biotechnologies (NASDAQ:ADPT) and Inhibikase Therapeutics (NYSE:IKT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, media sentiment, valuation, community ranking, dividends, earnings, institutional ownership and analyst recommendations. Do insiders & institutionals believe in ADPT or IKT? 99.2% of Adaptive Biotechnologies shares are held by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are held by institutional investors. 6.2% of Adaptive Biotechnologies shares are held by company insiders. Comparatively, 4.6% of Inhibikase Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media refer more to ADPT or IKT? In the previous week, Adaptive Biotechnologies had 7 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 7 mentions for Adaptive Biotechnologies and 0 mentions for Inhibikase Therapeutics. Adaptive Biotechnologies' average media sentiment score of 0.92 beat Inhibikase Therapeutics' score of 0.76 indicating that Adaptive Biotechnologies is being referred to more favorably in the media. Company Overall Sentiment Adaptive Biotechnologies Positive Inhibikase Therapeutics Positive Does the MarketBeat Community favor ADPT or IKT? Adaptive Biotechnologies received 86 more outperform votes than Inhibikase Therapeutics when rated by MarketBeat users. However, 90.00% of users gave Inhibikase Therapeutics an outperform vote while only 57.58% of users gave Adaptive Biotechnologies an outperform vote. CompanyUnderperformOutperformAdaptive BiotechnologiesOutperform Votes9557.58% Underperform Votes7042.42% Inhibikase TherapeuticsOutperform Votes990.00% Underperform Votes110.00% Do analysts prefer ADPT or IKT? Adaptive Biotechnologies presently has a consensus price target of $6.75, suggesting a potential upside of 5.63%. Inhibikase Therapeutics has a consensus price target of $6.50, suggesting a potential upside of 103.13%. Given Inhibikase Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Inhibikase Therapeutics is more favorable than Adaptive Biotechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adaptive Biotechnologies 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Inhibikase Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, ADPT or IKT? Adaptive Biotechnologies has a beta of 1.49, meaning that its share price is 49% more volatile than the S&P 500. Comparatively, Inhibikase Therapeutics has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500. Which has preferable earnings and valuation, ADPT or IKT? Inhibikase Therapeutics has lower revenue, but higher earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdaptive Biotechnologies$177.28M5.32-$225.25M-$1.34-4.77Inhibikase Therapeutics$260K826.99-$19.03M-$2.67-1.20 Is ADPT or IKT more profitable? Inhibikase Therapeutics has a net margin of 0.00% compared to Adaptive Biotechnologies' net margin of -110.13%. Adaptive Biotechnologies' return on equity of -62.06% beat Inhibikase Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Adaptive Biotechnologies-110.13% -62.06% -26.82% Inhibikase Therapeutics N/A -350.63%-201.82% SummaryAdaptive Biotechnologies beats Inhibikase Therapeutics on 11 of the 18 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get Inhibikase Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IKT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IKT vs. The Competition Export to ExcelMetricInhibikase TherapeuticsBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$215.02M$2.94B$5.12B$19.18BDividend YieldN/A1.90%4.91%3.59%P/E Ratio-1.2046.7391.3441.28Price / Sales826.99411.851,116.5917.59Price / CashN/A182.1042.6421.28Price / Book1.803.894.795.32Net Income-$19.03M-$42.21M$120.07M$989.88M7 Day Performance-6.98%-2.14%-1.89%-3.54%1 Month Performance59.20%4.21%11.45%-3.68%1 Year Performance153.97%18.40%30.61%12.14% Inhibikase Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IKTInhibikase Therapeutics2.3112 of 5 stars$3.20+1.3%$6.50+103.1%+152.0%$215.02M$260,000.00-1.208High Trading VolumeADPTAdaptive Biotechnologies2.9423 of 5 stars$6.64+5.4%$6.50-2.1%+34.8%$979.93M$170.28M-4.70709Analyst ForecastNews CoverageGap DownPSTXPoseida Therapeutics3.7522 of 5 stars$9.51flat$9.50-0.1%+193.5%$929.79M$64.70M-15.10260Positive NewsIMTXImmatics1.4116 of 5 stars$7.31+1.4%$16.67+128.0%-25.3%$872.49M$115.50M-10.92260LENZLENZ Therapeutics0.49 of 5 stars$31.34+1.2%$35.40+13.0%N/A$861.88MN/A0.00N/ANews CoveragePositive NewsREPLReplimune Group4.5416 of 5 stars$12.41-1.1%$17.29+39.3%+67.4%$849.09MN/A-4.11210Insider TradeRLAYRelay Therapeutics2.2525 of 5 stars$4.86+3.2%$20.50+321.8%-60.4%$813.47M$25.55M-1.80304Insider TradeAVXLAnavex Life Sciences3.3412 of 5 stars$9.33+10.3%$43.00+360.9%-2.5%$791.18MN/A-18.3640AUTLAutolus Therapeutics2.5518 of 5 stars$2.63+5.6%$10.40+295.4%-58.4%$699.82M$1.70M-2.06330CGEMCullinan Therapeutics1.8003 of 5 stars$11.81+0.5%$31.67+168.1%+32.7%$687.67M$18.94M-4.1430News CoverageTECXTectonic Therapeutic2.9296 of 5 stars$45.58+0.6%$72.25+58.5%N/A$672.44MN/A-7.70120Positive News Related Companies and Tools Related Companies ADPT Alternatives PSTX Alternatives IMTX Alternatives LENZ Alternatives REPL Alternatives RLAY Alternatives AVXL Alternatives AUTL Alternatives CGEM Alternatives TECX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:IKT) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibikase Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibikase Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
